Eyepoint Pharmaceuticals Stock Performance
| EYPT Stock | USD 14.05 0.15 1.08% |
On a scale of 0 to 100, Eyepoint Pharmaceuticals holds a performance score of 13. The firm shows a Beta (market volatility) of 0.96, which means possible diversification benefits within a given portfolio. Eyepoint Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Eyepoint Pharmaceuticals is expected to follow. Please check Eyepoint Pharmaceuticals' total risk alpha, as well as the relationship between the downside variance and daily balance of power , to make a quick decision on whether Eyepoint Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Eyepoint Pharmaceuticals are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, Eyepoint Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.08 | Five Day Return 4.62 | Year To Date Return 74.97 | Ten Year Return (60.53) | All Time Return (96.50) |
Last Split Factor 1:10 | Dividend Date 2020-12-09 | Last Split Date 2020-12-09 |
1 | Disposition of 7688 shares by Duker Jay S. of Eyepoint Pharmaceuticals at 11.06 subject to Rule 16b-3 | 07/10/2025 |
2 | Disposition of 2000 shares by Zaderej Karen L. of Eyepoint Pharmaceuticals subject to Rule 16b-3 | 07/11/2025 |
3 | EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635 EYPT Stock News | 07/16/2025 |
4 | EyePoint Pharmaceuticals, Inc. Q2 2025 Earnings Call Transcript | 08/07/2025 |
5 | How to recover losses in EyePoint Pharmaceuticals Inc. stock - 2025 Big Picture Scalable Portfolio Growth Ideas - Newser | 08/27/2025 |
6 | Applying Wyckoff theory to EyePoint Pharmaceuticals Inc. stock - Quarterly Trade Report Precise Swing Trade Alerts - Newser | 09/02/2025 |
7 | Eyepoint Pharmaceuticals Shares Down 4.4 percent - Heres What Happened - MarketBeat | 09/12/2025 |
8 | EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635 | 09/16/2025 |
9 | Eyepoint Pharmaceuticals, Inc. Receives Average Recommendation of Buy from Brokerages - MarketBeat | 09/18/2025 |
10 | Acquisition by George Elston of 20000 shares of Eyepoint Pharmaceuticals subject to Rule 16b-3 | 09/22/2025 |
11 | Biotech Stocks Rally. 3 Favorite Plays From the Charts. - Barrons | 09/23/2025 |
| Begin Period Cash Flow | 281.4 M | |
| Total Cashflows From Investing Activities | -219.4 M |
Eyepoint Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 966.00 in Eyepoint Pharmaceuticals on July 2, 2025 and sell it today you would earn a total of 439.00 from holding Eyepoint Pharmaceuticals or generate 45.45% return on investment over 90 days. Eyepoint Pharmaceuticals is currently generating 0.676% in daily expected returns and assumes 3.849% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Eyepoint, and 87% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Eyepoint Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eyepoint Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Eyepoint Pharmaceuticals, and traders can use it to determine the average amount a Eyepoint Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1756
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | EYPT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.85 actual daily | 34 66% of assets are more volatile |
Expected Return
| 0.68 actual daily | 13 87% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 13 87% of assets perform better |
Based on monthly moving average Eyepoint Pharmaceuticals is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Eyepoint Pharmaceuticals by adding it to a well-diversified portfolio.
Eyepoint Pharmaceuticals Fundamentals Growth
Eyepoint Stock prices reflect investors' perceptions of the future prospects and financial health of Eyepoint Pharmaceuticals, and Eyepoint Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Eyepoint Stock performance.
| Return On Equity | -0.74 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (11.67) % | ||||
| Current Valuation | 724.17 M | ||||
| Shares Outstanding | 68.93 M | ||||
| Price To Earning | (2.82) X | ||||
| Price To Book | 3.89 X | ||||
| Price To Sales | 18.66 X | ||||
| Revenue | 43.27 M | ||||
| Gross Profit | (133.71 M) | ||||
| EBITDA | (129.23 M) | ||||
| Net Income | (130.87 M) | ||||
| Cash And Equivalents | 171.17 M | ||||
| Cash Per Share | 5.02 X | ||||
| Total Debt | 21.86 M | ||||
| Debt To Equity | 0.30 % | ||||
| Current Ratio | 6.16 X | ||||
| Book Value Per Share | 3.57 X | ||||
| Cash Flow From Operations | (126.23 M) | ||||
| Earnings Per Share | (2.72) X | ||||
| Market Capitalization | 968.43 M | ||||
| Total Asset | 418.46 M | ||||
| Retained Earnings | (873.02 M) | ||||
| Working Capital | 334.26 M | ||||
| Current Asset | 15.08 M | ||||
| Current Liabilities | 11.26 M | ||||
About Eyepoint Pharmaceuticals Performance
Assessing Eyepoint Pharmaceuticals' fundamental ratios provides investors with valuable insights into Eyepoint Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Eyepoint Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 226.65 | 237.98 | |
| Return On Tangible Assets | (0.31) | (0.33) | |
| Return On Capital Employed | (0.39) | (0.41) | |
| Return On Assets | (0.31) | (0.33) | |
| Return On Equity | (0.39) | (0.41) |
Things to note about Eyepoint Pharmaceuticals performance evaluation
Checking the ongoing alerts about Eyepoint Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Eyepoint Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Eyepoint Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 43.27 M. Net Loss for the year was (130.87 M) with loss before overhead, payroll, taxes, and interest of (133.71 M). | |
| Eyepoint Pharmaceuticals currently holds about 171.17 M in cash with (126.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.02. | |
| Eyepoint Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: All You Need to Know About Kezar Life Sciences Rating Upgrade to Buy |
- Analyzing Eyepoint Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Eyepoint Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Eyepoint Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Eyepoint Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Eyepoint Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Eyepoint Pharmaceuticals' stock. These opinions can provide insight into Eyepoint Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.